Whilst elevated TGF-β levels have been observed in the AML BMM [133,134], predominantly upon release by megakaryocytes (MKs) and to a lesser extent by ECs [135], other studies reported decreased TGF-β levels in AML patients’ sera [136]. Here, TGFB1 is linked to acute myeloid leukemia.